Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Kohl’s Corporation: This Offprice Retailer Is Ready To Rally: https://www.marketbeat.com/logos/articles/med_20240301091400_chart-kss-312024ver001.png
Kohl’s Corporation: This Offprice Retailer Is Ready To Rally

Kohl’s Corporation (NYSE: KSS) stock price has been wallowing near long-term lows despite signs of turnaround and an improving outlook for cash flow. This market needs a catalyst to get it moving

5 Ways Ralph Lauren stock is Dressed for Success: https://www.marketbeat.com/logos/articles/med_20240301083323_5-ways-ralph-lauren-stock-is-dressed-for-success.jpg
5 Ways Ralph Lauren stock is Dressed for Success

Ralph Lauren Corp. (NYSE: RL) stock is in a buy range after its first pullback since gapping up almost 17% following better-than-expected fiscal third-quarter results.

The clothing maker, whose

Nvidia's Soaring Success: Too Late to Buy?: https://www.marketbeat.com/logos/articles/med_20240301081214_nvidias-soaring-success-too-late-to-buy.jpg
Nvidia's Soaring Success: Too Late to Buy?

At the forefront of the market surge stands Nvidia (NASDAQ: NVDA), continuing its meteoric rise into the new year. Last year’s champion stock has wasted no time in extending its winning streak,

Nvidia's Soaring Success: Too Late to Buy?: https://www.marketbeat.com/logos/articles/med_20240301081214_nvidias-soaring-success-too-late-to-buy.jpg
Nvidia's Soaring Success: Too Late to Buy?

At the forefront of the market surge stands Nvidia (NASDAQ: NVDA), continuing its meteoric rise into the new year. Last year’s champion stock has wasted no time in extending its winning streak,

Nvidia's Soaring Success: Too Late to Buy?: https://www.marketbeat.com/logos/articles/med_20240301081214_nvidias-soaring-success-too-late-to-buy.jpg
Nvidia's Soaring Success: Too Late to Buy?

At the forefront of the market surge stands Nvidia (NASDAQ: NVDA), continuing its meteoric rise into the new year. Last year’s champion stock has wasted no time in extending its winning streak,

Nvidia's Soaring Success: Too Late to Buy?: https://www.marketbeat.com/logos/articles/med_20240301081214_nvidias-soaring-success-too-late-to-buy.jpg
Nvidia's Soaring Success: Too Late to Buy?

At the forefront of the market surge stands Nvidia (NASDAQ: NVDA), continuing its meteoric rise into the new year. Last year’s champion stock has wasted no time in extending its winning streak,

3 Stocks Showing Constructive Pullbacks with Indexes at New Highs: https://www.marketbeat.com/logos/articles/med_20240301101105_3-stocks-showing-constructive-pullbacks-with-index.jpg
3 Stocks Showing Constructive Pullbacks with Indexes at New Highs

One of the most exciting things for an investor or trader is to look at tier account statement, or at the charts of what they own, and see a stock like Nvidia Corp. (NASDAQ: NVDA) or even the

3 Stocks Showing Constructive Pullbacks with Indexes at New Highs: https://www.marketbeat.com/logos/articles/med_20240301101105_3-stocks-showing-constructive-pullbacks-with-index.jpg
3 Stocks Showing Constructive Pullbacks with Indexes at New Highs

One of the most exciting things for an investor or trader is to look at tier account statement, or at the charts of what they own, and see a stock like Nvidia Corp. (NASDAQ: NVDA) or even the

3 Stocks Showing Constructive Pullbacks with Indexes at New Highs: https://www.marketbeat.com/logos/articles/med_20240301101105_3-stocks-showing-constructive-pullbacks-with-index.jpg
3 Stocks Showing Constructive Pullbacks with Indexes at New Highs

One of the most exciting things for an investor or trader is to look at tier account statement, or at the charts of what they own, and see a stock like Nvidia Corp. (NASDAQ: NVDA) or even the

Zscaler Stock Price Plunges: Buy the Dip Candidate: https://www.marketbeat.com/logos/articles/med_20240301074904_chart-zs-312024ver001.png
Zscaler Stock Price Plunges: Buy the Dip Candidate

Zscaler (NASDAQ: ZS) had a robust Q2 and raised its guidance, but it was not enough to lift the market. The results and valuation suggest the stock is priced to perfection following the

Zscaler Stock Price Plunges: Buy the Dip Candidate: https://www.marketbeat.com/logos/articles/med_20240301074904_chart-zs-312024ver001.png
Zscaler Stock Price Plunges: Buy the Dip Candidate

Zscaler (NASDAQ: ZS) had a robust Q2 and raised its guidance, but it was not enough to lift the market. The results and valuation suggest the stock is priced to perfection following the

3 Hot Stocks Bought by Members of Congress: Follow the Money: https://www.marketbeat.com/logos/articles/med_20240229123055_chart-spg-2292024ver001.png
3 Hot Stocks Bought by Members of Congress: Follow the Money

The STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let’s be honest. The STOCK Act can’t really stop Congresspeople from trading on insider knowledge; they’re in

3 Hot Stocks Bought by Members of Congress: Follow the Money: https://www.marketbeat.com/logos/articles/med_20240229123055_chart-spg-2292024ver001.png
3 Hot Stocks Bought by Members of Congress: Follow the Money

The STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let’s be honest. The STOCK Act can’t really stop Congresspeople from trading on insider knowledge; they’re in

Eilt: Sensationelle Krypto-Übernahme - Massives Kaufsignal. Aus 10.000 EUR wurden mit Bitcoin ($BTC) bis zu 1,34 Mrd. EUR. Neuer 421% Crypto Hot Stock nach 5.544% mit Ethereum ($ETH) und 1.337.328% mit Bitcoin ($BTC): https://www.irw-press.at/prcom/images/messages/2024/73798/ac-010324-2.001.png
Eilt: Sensationelle Krypto-Übernahme - Massives Kaufsignal. Aus 10.000 EUR wurden mit Bitcoin ($BTC) bis zu 1,34 Mrd. EUR. Neuer 421% Crypto Hot Stock nach 5.544% mit Ethereum ($ETH) und 1.337.328% mit Bitcoin ($BTC)

Eilt: Sensationelle Krypto-Übernahme - Massives Kaufsignal. 387% Crypto Hot Stock nach 1.337.328% mit Bitcoin ($BTC)

 

01.03.24 08:18

AC Research

 

Vancouver (www.aktiencheck.de , Anzeige)

 

Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73797/AC-010324.001.png
Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. 503% Biotech Aktientip nach 134.452% mit Biogen

 

01.03.24 08:03

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73797/AC-010324.001.png
Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. 503% Biotech Aktientip nach 134.452% mit Biogen

 

01.03.24 08:03

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2024/73797/AC-010324.001.png
Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. 503% Biotech Aktientip nach 134.452% mit Biogen

 

01.03.24 08:03

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

TJX Companies Stock: Take Profits or Buy the Dip?: https://www.marketbeat.com/logos/articles/med_20240229112922_chart-tjx-2292024-2ver001.png
TJX Companies Stock: Take Profits or Buy the Dip?

TJX Companies (NYSE: TJX) rallied strongly over the last few months but peaked following the Q4 release. The post-earnings action forms an ominous candle pattern that could lead to a significant

TJX Companies Stock: Take Profits or Buy the Dip?: https://www.marketbeat.com/logos/articles/med_20240229112922_chart-tjx-2292024-2ver001.png
TJX Companies Stock: Take Profits or Buy the Dip?

TJX Companies (NYSE: TJX) rallied strongly over the last few months but peaked following the Q4 release. The post-earnings action forms an ominous candle pattern that could lead to a significant

Salesforce.com Stock Will Set a New High This Year: https://www.marketbeat.com/logos/articles/med_20240229093245_chart-crm-2292024ver001.png
Salesforce.com Stock Will Set a New High This Year

Salesforce.com’s (NYSE: CRM) stock price is having trouble with traction following the Q4 results and guidance, but a massive correction is not expected for this tech stock. The results did not

Salesforce.com Stock Will Set a New High This Year: https://www.marketbeat.com/logos/articles/med_20240229093245_chart-crm-2292024ver001.png
Salesforce.com Stock Will Set a New High This Year

Salesforce.com’s (NYSE: CRM) stock price is having trouble with traction following the Q4 results and guidance, but a massive correction is not expected for this tech stock. The results did not

Salesforce.com Stock Will Set a New High This Year: https://www.marketbeat.com/logos/articles/med_20240229093245_chart-crm-2292024ver001.png
Salesforce.com Stock Will Set a New High This Year

Salesforce.com’s (NYSE: CRM) stock price is having trouble with traction following the Q4 results and guidance, but a massive correction is not expected for this tech stock. The results did not

bluebird bio Stock Signals Potential to be a Multi-bagger: https://www.marketbeat.com/logos/articles/med_20240229085127_bluebird-bio-stock-signals-potential-to-be-a-multi.jpg
bluebird bio Stock Signals Potential to be a Multi-bagger

It isn’t often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees

bluebird bio Stock Signals Potential to be a Multi-bagger: https://www.marketbeat.com/logos/articles/med_20240229085127_bluebird-bio-stock-signals-potential-to-be-a-multi.jpg
bluebird bio Stock Signals Potential to be a Multi-bagger

It isn’t often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees

bluebird bio Stock Signals Potential to be a Multi-bagger: https://www.marketbeat.com/logos/articles/med_20240229085127_bluebird-bio-stock-signals-potential-to-be-a-multi.jpg
bluebird bio Stock Signals Potential to be a Multi-bagger

It isn’t often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees